Modified Insulin Polypeptides and Their Uses

• US 20100298212A1
• Filed: 11/20/2008
• Published: 11/25/2010
• Est. Priority Date: 11/20/2007
• Status: Active Grant

• Current Assignee: Ambrx, Inc. (Johnson & Johnson)
• Original Assignee: Ambrx, Inc. (Johnson & Johnson)
• Inventors: Feng, Tian, Knudesen, Nick, Skidmore, Lillian, Deguzman, Michael, Miao, Zhenwei, Sim, Bee-Cheng, Kraynov, Vadim, Krawitz, Denise, Hays Putnam, Anna-Maria A.
• Granted Patent: US 8,946,148 B2
• Time in Patent Office: Days
• US Class Current: 514/5.9
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/62 Insulins

Abstract

Modified insulin polypeptides and their uses thereof are provided

Claims

1. An insulin polypeptide comprising one or more non-naturally encoded amino acids.

2. An insulin polypeptide wherein the A chain comprises one or more non-naturally encoded amino acids.

3. An insulin polypeptide wherein the B chain comprises one or more non-naturally encoded amino acids.

4. An insulin analog comprising one or more non-naturally encoded amino acids.

5. A method of treating a patient with a metabolic disorder wherein the patient is administered a therapeutically effective amount of an insulin polypeptide comprising one or more non-naturally encoded amino acids.